top of page
left-hand.webp
cape-bio-pharms-logo.png
right-hand.webp

OUR TECHNOLOGY

Our core business is plant-molecular pharming of recombinant proteins. Recombinant proteins (monoclonal antibodies, proteins, and enzymes) can be used as research or diagnostic reagents and, under GMP compliance regulations, as therapeutic or vaccine candidates.

 

Our transient plant-based expression technology provides unique benefits compared to traditional expression systems such as mammalian cell culture systems.
 

Click on the button below to learn more about our Technology. 

PARTNERING NATURE AND HEALTH

1654258264541.jfif

ABOUT US

Founded in 2018, Cape Bio Pharms (Pty Ltd) is the holding company for the group of Cape Biologix Technologies companies; Cape Biologix Technologies (SA) and Cape Biologix Technologies (MAU).

 

With its headquarters in Cape Town, South Africa, Cape Bio Pharms  drives innovation for the group by conducting product and process research, developing and owning the group's intellectual property. We also provide shared services (Finance, HR, IT, Procurement, etc) to our production subsidiaries.

For Investor Relations queries, please email investments@capebiopharms.com.

PIONEERS IN PLANT-BASED EXPRESSION

OUR PRODUCTS

Our ISO 13485 certified production subsidiaries provide a range of high quality recombinant proteins at affordable prices for customers all around the world.

 

Their services include product sales anywhere between small and large scale quantities, as well as R&D and OEM Agreements.

Click on the button below to explore our product range.

IN THE NEWS

The 5 hottest private biotechs in South Africa

International Society for Plant Molecular Farming (ISPMF) Newsletter Issue 23

Plant-based manufacturing of affordable proteins for use in diagnostics, diagnostics and therapeutics

The Technology Innovation Agency (TIA) and The SA SME Fund’s University Technology Fund (UTF) invests in blockbuster Covid-19 testing interventions

The Cape Bio-Pharms Story – Affordability and collaboration makes the Western Cape the ideal base for Bio-Pharm

Mauritius: EIB and FIND back innovative plant-based reagent manufacturing in Africa to fight COVID-19 and other endemic diseases

Austrian initiative Medicines for Future launches development of COVID-19 therapy with South Africa

UCT spin-off receives millions in European funding

EIB, FINDdx and CAPE : plant-based manufacturing of affordable proteins for use in diagnostics, diagnostics and therapeutics

PARTNERS

bru-bio-pharms-logo.png
european-ib-logo.png
uct.png
logo-cbt-d.png
dti-logo.png
plantform-logo.png

GET IN TOUCH

Please feel free to contact us via any of the options below, or by completing the form on the right.

LOCATION:
Unit 3, The Powder Mill
5 Sunrise Circle, Ndabeni, 7405
Cape Town, South Africa

Follow us on Social Media:

  • LinkedIn
  • Facebook
arrow&v

Thanks for submitting!

Newsletter Sign Up

Thanks for subscribing!

bottom of page